

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 18 October 2017, 10am to 5pm

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

| | | |
|-----------------|-------------------------|---------------------------|
| Present: | Dr Amanda Adler | Present for all notes |
| | Dr Sanjeev Patel | Present for all notes |
| | Dr Ray Armstrong | Present for all notes |
| | Professor John Cairns | Present for all notes |
| | Ms Susan Faulds | Present for all notes |
| | Dr Mark Glover | Present for all notes |
| | Dr Sumeet Gupta | Present for all notes |
| | Mr Richard James Hoddes | Present for all notes |
| | Dr Sanjay Kinra | Present for all notes |
| | Mr Christopher O'Regan | Present for all notes |
| | Dr Stephen Smith | Present for all notes |
| | Ms Marta Soares | Present for all notes |
| | Professor Ken Stein | Present for notes 1 to 27 |
| | Dr Nicky Welton | Present for all notes |
| | Mr Nigel Westwood | Present for all notes |
| | Dr Stuart Williams | Present for all notes |

In attendance:

| | | |
|---------------------|--|----------------------------|
| Bashama Anjum | Administrator, National Institute for Health and Care Excellence | Present for notes 1 to 27 |
| Lucy Beggs | Technical Analyst, National Institute for Health and Care Excellence | Present for notes 16 to 40 |
| Meindert Boysen | Programme Director, National Institute for Health and Care Excellence | Present for all notes |
| Ahmed Elsada | Technical Adviser, National Institute for Health and Clinical Excellence | Present for notes 1 to 15 |
| Dr Elisabeth George | Associate Director, National Institute for Health and Care Excellence | Present for all notes |
| Jasdeep Hayre | Technical Adviser, National Institute for | Present for notes 16 to 39 |

| | | |
|-----------------------|--|----------------------------|
| Boglarka Mikudina | Health and Clinical Excellence Technical Analyst, National Institute for Health and Care Excellence | Present for notes 1 to 15 |
| Kirsty Pitt | Technical Analyst, National Institute for Health and Care Excellence | Present for notes 16 to 27 |
| Jeremy Powell | Project Manager, National Institute for Health and Care Excellence | Present for all notes |
| Dr Joanne Ablett | Consultant Clinical Psychologist, Salford Royal foundation Trust, clinical expert nominated by Shire | Present for notes 1 to 15 |
| Professor Peter Clark | Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF, NHSE commissioning expert nominated by NHSE | Present for notes 28 to 40 |
| Mary Foss | Chair of Short Bowel Survivor and Friends, patient expert nominated by Short Bowel Survivor and Friends | Present for notes 1 to 15 |
| Dr Jonathan Hind | Consultant in Paediatric Hepatology, Kings College Hospital, clinical expert nominated by Shire | Present for notes 1 to 15 |
| Andy Hughes | Manager Internal Medicine National Programme of Care, NHS England, NHSE commissioning expert nominated by NHS England | Present for notes 1 to 15 |
| Professor Simon Lal | Professor of Gastroenterology, Salford Royal Foundation Trust, clinical expert nominated by Shire | Present for notes 1 to 15 |
| Dr Farooq Rahman | Consultant Gastroenterologist, University College London Hospitals, clinical expert nominated by Shire | Present for notes 1 to 15 |
| Carolyn Wheatley | Chair of PINNT, patient expert nominated by | Present for notes 1 to 15 |

| | | |
|-----------------------|---|----------------------------|
| Miriam Brazzelli | PINNT Senior Research Fellow, Evidence Review Group – Aberdeen HTA Group | Present for notes 1 to 15 |
| Nasuh Buyukkaramikli | Evidence Review Group - Kleijnen Systematic Reviews | Present for notes 16 to 40 |
| Moira Cruickshank | Research Fellow, Evidence Review Group – Aberdeen HTA Group | Present for notes 1 to 15 |
| Rodolfo Hernandez | Research Fellow, Evidence Review Group – Aberdeen HTA Group | Present for notes 1 to 15 |
| Professor James Mason | Professor of Health Economics, Evidence Review Group – Warwick Evidence | Present for notes 16 to 27 |
| Graham Scotland | Senior Research Fellow, Evidence Review Group – Aberdeen HTA Group | Present for notes 1 to 15 |

Non-public observers:

| | | |
|-------------------|---|-----------------------------|
| Helen Barnett | Senior Medical Editor, NICE | Present for notes all notes |
| Michael King | Project Manager, CHTE NICE | Present for notes all notes |
| Heidi Livingstone | Senior Public Involvement Advisor, NICE | Present for notes all notes |
| Edgar Masanga | Business Analyst - Resource Impact Assessment, Implementation, NICE | Present for notes all notes |
| Amy Thomas | Communications Apprentice (media relations) NICE | Present for notes all notes |

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of teduglutide for treating short bowel syndrome [ID885], lesinurad for treating chronic hyperuricaemia in people with gout [ID761] and obinutuzumab for untreated advanced follicular lymphoma [ID1020].
2. Apologies were received from Mr Mark Chapman, Mr Diar Fattah, Dr Miriam McCarthy, Professor Stephen Palmer and Dr Danielle Preedy.

Any other Business

3. None

Appraisal of teduglutide for treating short bowel syndrome [ID885]

Part 1 – Open session

4. The Chair welcomed the invited experts: Miriam Brazzelli, Moira Cruickshank, Rodolfo Hernandez and Graham Scotland to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from Shire to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
 - 6.1. Dr Sanjeev Patel, Dr Ray Armstrong, Professor John Cairns, Ms Susan Faulds, Dr Mark Glover, Dr Sumeet Gupta, Mr Richard James Hoddes, Dr Sanjay Kinra, Mr Christopher O'Regan, Dr Stephen Smith, Ms Marta Soares, Professor Ken Stein, Dr Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of teduglutide for treating short bowel syndrome [ID885].
7. The Chair asked all NICE Staff to declare any relevant interests.
 - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of teduglutide for treating short bowel syndrome [ID885].
8. The Chair asked all other invited guests Dr Joanne Ablett, Mary Foss, Dr Jonathan Hind, Andy Hughes, Professor Simon Lal, Dr Farooq Rahman, Carolyn Wheatley, Miriam Brazzelli, Moira Cruickshank, Rodolfo Hernandez and Graham Scotland to declare their relevant interests.
 - 8.1. Andy Hughes, Miriam Brazzelli, Moira Cruickshank, Rodolfo Hernandez and Graham Scotland declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of teduglutide for treating short bowel syndrome [ID885].
 - 8.2. Dr Joanne Ablett declared a personal specific financial interest as she has received honoraria and funding for attending conferences from Shire.
 - 8.2.1. It was agreed that this declaration would not prevent Dr Ablett from participating in this section of the meeting
 - 8.3. Mrs Mary Foss declared a personal specific financial interest as she has received funding from Shire to attend some workshops for patient organisations.
 - 8.3.1. It was agreed that this declaration would not prevent Mrs Foss from participating in this section of the meeting

- 8.4. Dr Jonathan Hind declared a personal specific financial interest as he has served on an advisory board for Shire and received funding to attend a conference.
 - 8.4.1. It was agreed that this declaration would not prevent Dr Hind from participating in this section of the meeting
- 8.5. Professor Simon Lal declared a personal specific financial interest as he has received honoraria and funding for attending conferences from Shire. His department also receives support for research from Shire.
 - 8.5.1. It was agreed that this declaration would not prevent Professor Lal from participating in this section of the meeting
- 8.6. Dr Farooq Rahman declared a personal specific financial interest as he has received honoraria for attending advisory boards and funding for attending conferences from Shire. His department also receives support for research from Shire.
 - 8.6.1. It was agreed that this declaration would not prevent Dr Rahman from participating in this section of the meeting
- 8.7. Mrs Carolyn Wheatley declared a personal specific financial interest as PINNT has received a grant from Shire and she has received expenses for training sessions.
 - 8.7.1. It was agreed that this declaration would not prevent Mrs Wheatley from participating in this section of the meeting

9. The Chair introduced the lead team, Sanjay Kinra, Nicky Welton and Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of teduglutide for treating short bowel syndrome [ID885].
10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
11. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
12. The Chair then thanked the experts, Evidence Review Group and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.
14. The Committee continued to discuss the clinical and cost effectiveness of teduglutide for treating short bowel syndrome [ID885].
 - 14.1. The committee decision was based on consensus.
15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of lesinurad for treating chronic hyperuricaemia in people with gout [ID761]

Part 1 – Open session

16. The Chair welcomed the invited experts: Professor James Mason to the meeting and he introduced himself to the Committee.
17. The Chair welcomed company representatives from Grunenthal to the meeting.
18. The Chair asked all Committee members to declare any relevant interests
 - 18.1. Dr Sanjeev Patel, Dr Ray Armstrong, Professor John Cairns, Ms Susan Faulds, Dr Mark Glover, Dr Sumeet Gupta, Mr Richard James Hoddes, Dr Sanjay Kinra, Mr Christopher O'Regan, Dr Stephen Smith, Ms Marta Soares, Professor Ken Stein, Dr Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lesinurad for treating chronic hyperuricaemia in people with gout [ID761].
19. The Chair asked all NICE Staff to declare any relevant interests.
 - 19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lesinurad for treating chronic hyperuricaemia in people with gout [ID761].
20. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 20.1. Professor James Mason declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lesinurad for treating chronic hyperuricaemia in people with gout [ID761].
21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
23. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be

prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

24. The Chair then thanked the Evidence Review Group and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

25. Discussion on confidential information continued. This information was supplied by the company.
26. The Committee continued to discuss the clinical and cost effectiveness of lesinurad for treating chronic hyperuricaemia in people with gout [ID761].
 - 26.1. The committee decision was based on consensus.
27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD)] in line with their decisions.

Appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020]

Part 1 – Open session

28. The Chair welcomed the invited experts: Nasuh Buyukkaramikli and Professor Peter Clark to the meeting and they introduced themselves to the Committee.
29. The Chair welcomed company representatives from Roche to the meeting.
30. The Chair asked all Committee members to declare any relevant interests
 - 30.1. Dr Sanjeev Patel, Dr Ray Armstrong, Professor John Cairns, Ms Susan Faulds, Dr Mark Glover, Dr Sumeet Gupta, Mr Richard James Hoddes, Dr Sanjay Kinra, Mr Christopher O'Regan, Dr Stephen Smith, Ms Marta Soares, Dr Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
 - 30.2. Professor Ken Stein declared a personal specific financial interest before the meeting as he has participated on an advisory board for Roche in another disease area.
 - 9.3.1 It was agreed that this declaration would prevent Professor Ken Stein from participating in this section of the meeting.
31. The Chair asked all NICE Staff to declare any relevant interests.
 - 31.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the

technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].

32. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
33. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
34. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
35. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
36. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

37. Discussion on confidential information continued. This information was supplied by the company.
38. The Evidence Review Group representative left the meeting.
39. The Committee continued to discuss the clinical and cost effectiveness of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
 - 39.1. The committee decision was based on consensus.
40. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD)] in line with their decisions.

Date, time and venue of the next meeting

Technology Appraisal (Committee B) Meeting: Thursday, 16 November 2017 10:00, National Institute for Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU